For instance, the PNPLA3 rs738409 C > G and TM6SF2 rs58542926 C > T are two genotypes that increase the risk of developing advanced forms of NAFLD [57], but may also promote the reduction in plasma very-low-density lipoprotein (VLDL) concentrations, thereby reducing the risk of cardiovascular disease in patients with NAFLD [57]. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.